查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933845

末期腎功能衰竭治療市場按治療類型、最終用戶和分銷管道分類，全球預測（2026-2032年）

End-stage Renal Disease Therapeutics Market by Therapy Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年末末期腎功能衰竭治療市值為670.5億美元，預計2026年將成長至707.3億美元，年複合成長率為4.17%，到2032年將達到892.9億美元。

關鍵市場統計數據
基準年 2025 670.5億美元
預計年份：2026年 707.3億美元
預測年份 2032 892.9億美元
複合年成長率 (%) 4.17%

全面實施末期腎功能衰竭護理：重點關注不斷變化的臨床重點、患者就醫歷程和跨學科護理整合

本概要概述了當代末期腎功能衰竭治療的臨床、運作和商業性層面。它重點介紹了重點患者群體、常見合併症和治療路徑銜接，並強調了藥物治療和腎臟替代療法之間的相互作用。透過將治療置於連續性照護框架中，它闡述了不斷變化的實踐模式、技術進步和支付方期望如何重塑治療決策和醫療服務提供者的責任。

臨床實踐、報銷模式以及技術賦能的家庭護理方面的變革性變化正在重塑不同護理機構中的患者就醫途徑和臨床醫生工作流程。

末期腎病治療領域正經歷多重變革，這些變革對醫療服務提供者、製造商和醫療保健系統都產生了影響。臨床實踐日益注重個別化治療，治療方案的選擇綜合考慮了患者的合併症情況、實際用藥依從性以及家庭治療的選擇範圍。同時，報銷機制和政策調整正在重塑醫療服務的獎勵，推動縮短住院時間、採用統一支付方式以及以結果而非數量為導向的價值導向合約。

預計2025年美國關稅趨勢將對腎臟藥物供應鏈、籌資策略、成本結構和全球採購產生累積影響

預計2025年美國關稅政策的累積影響將波及腎臟治療藥物的採購、生產和分銷環節，但不會改變該療法的臨床原理。關稅變化將影響進口原料藥、透析耗材和資本財的成本基礎，促使供應鏈管理人員重新評估採購區域並調整庫存策略。為此，預計相關人員將更加重視供應商多元化、盡可能選擇近岸外包以及採用雙重採購策略，以降低對單一國家的依賴風險。

關鍵的細分洞察，整合了治療領域、透析方式、終端用戶給藥途徑和分銷管道，為產品定位提供了寶貴的資訊。

關鍵的細分洞察突顯了臨床需求、營運可行性和商業性機會的交集，而這又基於治療類別、給藥方式和分銷管道之間的相互作用。按治療類型分類，藥物治療和腎臟替代療法是重點領域。在藥物治療方面，主要藥物類別——鈣敏感受體激動劑、促紅血球生成素、鐵劑、磷酸鹽粘合劑和維生素D類似物——在療效、安全性和給藥方式方面各有優劣，這些優劣會影響處方決策和依從性計畫。腎臟替代療法包括血液透析、腹膜透析和腎臟移植。血液透析再細分為居家透析和中心透析，腹膜透析則細分為自動腹膜透析和持續性攜帶式透析。這些治療方法之間的差異對於設備相容性、培訓需求和急性後期護理協調至關重要。

美洲、歐洲、中東和非洲以及亞太地區的戰略區域觀點重點關注醫療服務取得趨勢、臨床基礎設施和政策槓桿。

區域洞察揭示了政策環境、臨床基礎設施和患者人口結構如何影響美洲、歐洲、中東和非洲以及亞太地區的醫療服務模式和營運實踐。在美洲，醫療服務通常需要在先進的中心透析能力與日益成長的家庭治療和移植計畫需求之間取得平衡。這主要由強調協調慢性病管理的支付者和綜合醫療網路推動。要在此基礎上進行轉變，製造商和服務供應商需要建立客製化的合作策略，以反映不同的支付方模式和集中化的卓越中心。

領先製造商、技術提供者和服務網路之間的競爭和聯盟動態正在推動創新、試驗設計和商業化策略。

對主要企業的深入分析凸顯了競爭定位、合作聯盟和服務差異化如何塑造創新軌跡和市場行為。領先的製造商和技術供應商正在加速將其藥品組合與醫療設備和數位化賦能相結合，以提供能夠同時解決臨床療效和依從性障礙的綜合解決方案。這種整合也延伸至與學術機構和醫療系統在臨床試驗設計方面的夥伴關係，從而能夠產生可操作的證據，證明其在不同醫療環境中的真實療效。

為實現可衡量的營運和臨床改進，提出切實可行的建議，以協調臨床開發、供應鏈韌性和以患者為中心的服務模式。

切實可行的建議鼓勵行業領導者將臨床開發、營運韌性和以患者為中心的醫療服務相結合，以創造永續價值並改善治療效果。首先，優先考慮可適用於血液透析、腹膜透析和移植治療路徑的模組化產品和服務設計，確保臨床證據的生成能夠滿足每種治療方法的獨特終點。其次，透過採購多元化策略、提高對一級和二級供應商的透明度以及建立能夠分散海關和物流風險並維持品管的合約框架，來增強供應鏈韌性。

穩健的混合方法調查方法：資料來源、相關人員參與、檢驗過程和分析架構均有明確的定義，以確保研究的嚴謹性和相關性。

為確保調查方法採用混合方法，結合了與關鍵相關人員的直接對話、二手文獻綜合分析和質性檢驗。直接對話包括與臨床醫生、採購專業人員、支付方和技術合作夥伴進行結構化訪談，以收集關於治療選擇、模式採納和分銷實踐的實際觀點。這些訪談為假設驅動型問卷的製定提供了依據，並有助於對營運挑戰和創新重點進行三角驗證。

一份全面的綜合報告，重點闡述了尚未滿足的需求、轉換差距和策略轉折點，旨在指導研發、商業化和支付方參與計劃。

總之，目前末期腎功能衰竭治療面臨多重交織的壓力和機遇，需要臨床、商業和營運等相關人員的協調應對。在最佳化貧血管理、控制礦物質和骨骼疾病、以及從透析到腎臟移植的以患者為中心的護理服務等方面，仍存在諸多未滿足的需求；此外，在將基於設備和數位化的干涉措施從試點階段推廣到常規臨床實踐方面，也存在轉化方面的差距。策略轉折點包括擴大家庭治療方法、推出整合治療和服務的捆綁式解決方案，以及根據關稅和地緣政治風險調整供應鏈。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類型末期腎功能衰竭治療市場

  • 藥物治療
    • 鈣模擬物
    • 紅血球生成刺激因子
    • 鐵劑治療
    • 磷酸鹽粘合劑
    • 維生素D類似物
  • 腎臟替代療法
    • 血液透析
    • 腹膜透析
      • 自動化
      • 持續攜帶式
    • 移植

第9章末期腎功能衰竭治療市場（依最終用戶分類）

  • 透析中心
  • 居家醫療環境
  • 醫院

第10章 按分銷管道分類的末期腎功能衰竭治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章末期腎功能衰竭治療市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 按組別末期腎功能衰竭治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國末期腎功能衰竭治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 美國：末期腎功能衰竭治療市場

第15章 中國：末期腎功能衰竭治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Asahi Kasei Corporation
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • Cantel Medical Corporation
  • DaVita Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc
  • JMS Co., Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Medtronic plc
  • Mitsubishi Tanabe Pharma Corporation
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Rockwell Medical, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Toray Medical Co., Ltd.
  • Vifor Pharma Group Ltd
Product Code: MRR-C36616F6997B

The End-stage Renal Disease Therapeutics Market was valued at USD 67.05 billion in 2025 and is projected to grow to USD 70.73 billion in 2026, with a CAGR of 4.17%, reaching USD 89.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 67.05 billion
Estimated Year [2026] USD 70.73 billion
Forecast Year [2032] USD 89.29 billion
CAGR (%) 4.17%

Comprehensive introduction to end-stage renal disease therapeutics highlighting evolving clinical priorities, patient journeys, and cross-disciplinary care integration

This executive introduction establishes a concise orientation to the clinical, operational, and commercial dimensions that define contemporary end-stage renal disease therapeutics. It frames priority patient populations, common comorbidities, and care pathway touchpoints while emphasizing the interplay between pharmacologic management and renal replacement modalities. By situating therapies within the continuum of care, the introduction highlights how shifts in practice patterns, technology diffusion, and payer expectations combine to reshape treatment decisions and provider responsibilities.

In addition, the introduction outlines the roles of multidisciplinary teams-nephrologists, dialysis nurses, transplant coordinators, and primary care clinicians-in coordinating long-term care. It also describes how patient preferences, particularly regarding quality of life and home-based options, are increasingly central to therapeutic selection and adherence strategies. Finally, the introduction sets expectations for the rest of the report by identifying major themes-innovation in drug classes, expansion of home dialysis, supply chain resilience, and evolving distribution channels-that will be explored in depth and tied back to actionable implications for clinical leaders, manufacturers, and health system executives.

Transformative shifts in clinical practice, reimbursement models, and technology-enabled home therapies reshaping patient access and clinician workflows across care settings

The landscape for end-stage renal disease is in the midst of several transformative shifts that affect clinicians, manufacturers, and health systems alike. Clinical practice is moving toward greater personalization of therapy, where treatment selection integrates patient comorbidity profiles, real-world adherence patterns, and the growing availability of home-based modalities. At the same time, reimbursement and policy levers are recalibrating incentives for care delivery, encouraging shorter in-center encounters, bundled payment approaches, and value-based arrangements that reward outcomes rather than volume.

Technological advances are accelerating change through improved dialysis equipment, telehealth-enabled monitoring, and digital adherence tools that link patients to care teams in real time. These innovations are complemented by evolving drug development strategies, including therapies that target mineral bone disease, anemia, and iron management with refined safety profiles and administration conveniences. As a result, provider workflows are adapting: care coordination demands more integrated data flows, supply chain practices prioritize just-in-time resilience, and commercial models increasingly emphasize integrated service offerings that combine devices, therapies, and digital support. These converging shifts are not isolated; rather, they interact to create new opportunities for differentiated patient outcomes and novel business models across the renal care ecosystem.

Anticipated cumulative implications of United States tariff developments in 2025 on supply chains, sourcing strategies, cost structures, and global procurement of renal therapeutics

The cumulative impact of United States tariff developments in 2025 will reverberate through procurement, manufacturing, and distribution practices relevant to renal therapeutics without altering the clinical rationale for treatment. Tariff changes influence the cost basis for imported active pharmaceutical ingredients, dialysis consumables, and capital equipment, prompting supply chain managers to reassess sourcing geographies and inventory policies. In response, stakeholders are likely to emphasize supplier diversification, nearshoring where feasible, and dual-sourcing strategies to reduce exposure to single-country disruptions.

Beyond sourcing, tariff dynamics also affect contractual arrangements with distributors and hospital purchasing groups. Procurement teams increasingly negotiate terms that allocate risk or include price adjustment provisions that trigger under specified tariff events. At the same time, manufacturers and distributors may accelerate localization of manufacturing for high-volume components or invest in tariff classification and customs optimization to mitigate incremental costs. Importantly, these operational responses feed into broader strategic choices: product launch sequencing, contract structuring for bundled services, and partnership models that aggregate purchasing power across health systems. Throughout, regulatory compliance and quality assurance remain non-negotiable, so mitigation efforts must preserve traceability and adherence to good manufacturing and distribution practices while seeking cost-efficiency.

Key segmentation insights synthesizing therapeutic classes, dialysis modalities, end-user delivery pathways, and distribution channels to inform product positioning

Key segmentation insights draw on the interplay between therapeutic categories, delivery modalities, and channel dynamics to reveal where clinical need, operational feasibility, and commercial opportunity converge. Based on therapy type, the landscape includes drug therapy and renal replacement therapy. Within drug therapy, important classes such as calcimimetics, erythropoiesis stimulating agents, iron therapies, phosphate binders, and vitamin D analogs each present distinct efficacy, safety, and administration trade-offs that influence formulary decisions and adherence support programs. Renal replacement therapy spans hemodialysis, peritoneal dialysis, and transplant, with hemodialysis further differentiated into home and in-center settings and peritoneal dialysis split between automated and continuous ambulatory approaches; these modality distinctions matter for device compatibility, training needs, and post-acute care coordination.

From an end-user perspective, treatment pathways are shaped by dialysis centers, home care settings, and hospitals, which have differing operational capabilities, staffing models, and procurement channels. Distribution pathways likewise influence access and service expectations, with hospital pharmacy, online pharmacy, and retail pharmacy options each providing distinct benefits for dispensing, reimbursement handling, and patient convenience. Taken together, these segmentation layers imply that successful product positioning requires aligning clinical messaging to therapy class, designing services that accommodate modality-specific workflows, and selecting distribution strategies that match the purchasing behavior and logistical capacities of dialysis centers, home care organizations, and hospitals.

Strategic regional perspectives across the Americas, Europe Middle East & Africa, and Asia-Pacific highlighting access dynamics, clinical infrastructure, and policy levers

Regional insights reveal how policy environments, clinical infrastructure, and patient demographics shape adoption patterns and operational practices across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care delivery typically balances advanced in-center dialysis capacity with growing interest in home therapies and transplant programs, driven by payers and integrated delivery networks that value coordinated chronic care management. Transitioning from this baseline, manufacturers and service providers must tailor engagement strategies to reflect diverse payer models and concentrated centers of excellence.

Across Europe Middle East & Africa, variations in public funding, regulatory approval pathways, and infrastructural maturity create heterogeneous access patterns; some markets prioritize centralized hospital-based care while others have progressive reimbursement for home-based modalities. Consequently, stakeholders often pursue differentiated go-to-market strategies that emphasize local partnerships and adaptable service bundles. In the Asia-Pacific region, demographic trends and rising chronic disease burdens intersect with rapid scale-up of dialysis capacity and an expanding private sector role, creating opportunities for innovative financing models, capacity-building programs, and digital solutions that support remote monitoring and workforce training. Together, these regional dynamics underscore the importance of customizing clinical support, supply chain models, and stakeholder engagement to regional policy, infrastructure, and patient preference profiles.

Competitive and partnership dynamics among leading manufacturers, technology providers, and service networks driving innovation, trial design, and commercialization strategies

Insights about key companies emphasize how competitive positioning, collaborative alliances, and service differentiation shape innovation trajectories and market behavior. Leading manufacturers and technology providers are increasingly integrating drug portfolios with devices and digital support to deliver bundled solutions that address both clinical outcomes and adherence barriers. This integration extends to trial design partnerships with academic centers and health systems, enabling pragmatic evidence generation that demonstrates real-world effectiveness in diverse care settings.

Partnerships between device makers, pharmaceutical firms, and third-party service organizations are also accelerating, focusing on patient monitoring, remote training for home modalities, and logistics optimization. These collaborations frequently aim to reduce total cost of care while enhancing patient-centered outcomes, making it easier for providers and payers to adopt new treatment approaches. Additionally, companies that invest in robust post-market surveillance and transparent safety reporting tend to build higher trust among clinicians and procurement teams, creating durable commercial advantages. Overall, the most successful corporate strategies combine clinical credibility, supply chain reliability, and an ability to co-create service models with healthcare delivery partners.

Actionable recommendations to align clinical development, supply resilience, and patient-centered delivery models for measurable operational and clinical improvements

Actionable recommendations encourage industry leaders to align clinical development, operational resilience, and patient-centered delivery to capture sustainable value and improve outcomes. First, prioritize modular product and service designs that can be adapted across hemodialysis, peritoneal dialysis, and transplant pathways, and ensure clinical evidence generation addresses modality-specific endpoints. Second, build supply chain resilience through diversified sourcing strategies, enhanced visibility into tier-one and tier-two suppliers, and contractual frameworks that distribute tariff and logistics risks while preserving quality controls.

Third, engage payers and provider networks early to co-design reimbursement models and value-based contracting pilots that reflect meaningful patient outcomes and utilization patterns. Fourth, invest in clinician and patient education programs that facilitate transition to home-based therapies, leveraging telehealth and digital adherence tools to maintain clinical oversight and reduce readmissions. Finally, pursue strategic partnerships-both local and regional-that accelerate market entry, support regulatory navigation, and localize manufacturing or service delivery where necessary. Implementing these recommendations requires cross-functional alignment between clinical development, commercial strategy, supply chain, and health economics teams to translate insights into measurable operational and clinical improvements.

Robust mixed-methods research methodology outlining data sources, stakeholder engagement, validation processes, and analytical frameworks used to ensure rigor and relevance

The research methodology rests on a mixed-methods approach that combines primary stakeholder engagement, secondary literature synthesis, and qualitative validation to ensure rigor and relevance. Primary engagement included structured interviews with clinicians, procurement specialists, payers, and technology partners to capture frontline perspectives on treatment selection, modality adoption, and distribution practices. These interviews informed the development of hypothesis-driven inquiry and enabled triangulation of operational pain points and innovation priorities.

Secondary synthesis drew on peer-reviewed clinical literature, regulatory guidance documents, and public policy announcements to contextualize clinical efficacy, safety considerations, and reimbursement trends. The analytical framework incorporated thematic coding of qualitative inputs, comparative assessments across therapy classes and modalities, and scenario-based analysis to evaluate supply chain and policy impacts. Validation steps included expert review panels and iterative feedback sessions with domain specialists to refine interpretations and ensure the final deliverables reflect both clinical realities and practical commercial considerations. Throughout the process, data integrity, transparency of assumptions, and reproducibility of analytical steps were prioritized to deliver actionable intelligence for decision-makers.

Concluding synthesis articulating unmet needs, translational gaps, and strategic inflection points to guide research and development, commercialization, and payer engagement plans

In conclusion, the end-stage renal disease therapeutics landscape is characterized by converging pressures and opportunities that require coordinated responses from clinical, commercial, and operational stakeholders. Unmet needs persist in the optimization of anemia management, mineral bone disease control, and patient-centered delivery across dialysis and transplant pathways, while translational gaps remain in moving device-enabled and digital interventions from pilot phases to routine clinical practice. Strategic inflection points include the scaling of home modalities, the integration of bundled solutions that combine therapies and services, and the reconfiguration of supply chains in light of tariff and geopolitical risks.

For decision-makers, the implications are clear: prioritize evidence generation that addresses real-world outcomes, structure partnerships that accelerate delivery capacity and patient access, and establish procurement and contractual practices that balance cost, quality, and resilience. By aligning R&D priorities with operational realities and payer expectations, organizations can better position themselves to deliver measurable clinical improvements and sustainable commercial performance. The synthesis presented here points to concrete areas where investment and collaboration will yield the greatest downstream impact on patient care and system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. End-stage Renal Disease Therapeutics Market, by Therapy Type

  • 8.1. Drug Therapy
    • 8.1.1. Calcimimetics
    • 8.1.2. Erythropoiesis Stimulating Agents
    • 8.1.3. Iron Therapies
    • 8.1.4. Phosphate Binders
    • 8.1.5. Vitamin D Analogs
  • 8.2. Renal Replacement Therapy
    • 8.2.1. Hemodialysis
    • 8.2.2. Peritoneal Dialysis
      • 8.2.2.1. Automated
      • 8.2.2.2. Continuous Ambulatory
    • 8.2.3. Transplant

9. End-stage Renal Disease Therapeutics Market, by End User

  • 9.1. Dialysis Centers
  • 9.2. Home Care Settings
  • 9.3. Hospitals

10. End-stage Renal Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. End-stage Renal Disease Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. End-stage Renal Disease Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. End-stage Renal Disease Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States End-stage Renal Disease Therapeutics Market

15. China End-stage Renal Disease Therapeutics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Amgen Inc.
  • 16.6. Asahi Kasei Corporation
  • 16.7. AstraZeneca plc
  • 16.8. B. Braun Melsungen AG
  • 16.9. Baxter International Inc.
  • 16.10. Bayer AG
  • 16.11. Cantel Medical Corporation
  • 16.12. DaVita Inc.
  • 16.13. Eli Lilly and Company
  • 16.14. F. Hoffmann-La Roche Ltd
  • 16.15. Fresenius Kabi
  • 16.16. Fresenius Medical Care AG & Co. KGaA
  • 16.17. GlaxoSmithKline plc
  • 16.18. JMS Co., Ltd.
  • 16.19. Johnson & Johnson
  • 16.20. Kyowa Kirin Co., Ltd.
  • 16.21. Medtronic plc
  • 16.22. Mitsubishi Tanabe Pharma Corporation
  • 16.23. Nikkiso Co., Ltd.
  • 16.24. Nipro Corporation
  • 16.25. Novartis AG
  • 16.26. NxStage Medical, Inc.
  • 16.27. Otsuka Pharmaceutical Co., Ltd.
  • 16.28. Pfizer Inc.
  • 16.29. Rockwell Medical, Inc.
  • 16.30. Sanofi S.A.
  • 16.31. Takeda Pharmaceutical Company Limited
  • 16.32. Toray Medical Co., Ltd.
  • 16.33. Vifor Pharma Group Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 132. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)